Controlling the gene for the 'immortalizing enzyme'

November 16, 2018, Agency for Science, Technology and Research (A*STAR), Singapore
Controlling the gene for the ‘immortalizing enzyme’
Molecular strand and surface outline representations of the structure of the complex between two proteins (p52 and ETS1) that can reactivate the TERT gene’s mutated DNA, with a possible site to target with drugs circled. Credit: A*STAR Institute of Molecular and Cell Biology

Revealing how a gene is activated in cancer cells to produce an enzyme that helps the cells thrive could lead to new treatments.

"We are investigating one of the most fundamental questions in ," says lead researcher, Haiwei Song from the A*STAR Institute of Molecular and Cell Biology. The team has been studying the that underpin a genetic malfunction found in up to 95 per cent of human cancers. Their findings could lead to new treatments.

Together with colleagues in France, the team has examined processes that activate the gene coding for a protein known as "the immortalizing enzyme." The dramatic name recognizes the enzyme's ability to allow to survive and multiply, in defiance of normal controls on cell growth.

The enzyme, more formally known as telomerase reverse transcriptase (TERT), maintains regions of DNA called telomeres found at the end of chromosomes, which naturally shorten as cells age and die. This maintenance is essential for cells, such as stem cells, that must survive to build healthy bodies.

But the reactivation of the gene for TERT in cells where it should normally be shut down is one of the central processes that allows cancer to multiply into life-threatening tumors. This undesirable reactivation can be caused by mutations in regions of DNA that control the activity of TERT's gene, which enable a complex of two regulatory proteins to bind to the mutated DNA and switch on the TERT gene activity.

The A*STAR researchers made and analyzed crystals of the complex between the two proteins and the mutated DNA. This revealed the precise structure of the complex (see image) and details of the mechanism behind its effect.

The research also showed that one of the proteins of the complex can interfere with cell signaling systems to reactivate the TERT gene even without binding to DNA.

"This was a surprise," says Song, especially as it may mean that many other could potentially be activated in a similar way.

"We plan to use our understanding of this system to make new drugs," says Song. He explains that one option is to find that inhibit the reactivation of the TERT gene, for example, by binding to the proteins or the DNA involved. Liver cancer may be the first target, as this often involves mutations in the TERT gene that take effect in the early stages of tumor development.

Explore further: Researchers unlock secret of deadly brain cancer's 'immortality'

More information: Xueyong Xu et al. Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1, Nature Communications (2018). DOI: 10.1038/s41467-018-05644-0

Related Stories

Researchers unlock secret of deadly brain cancer's 'immortality'

September 10, 2018

UC San Francisco researchers have discovered how a mutation in a gene regulator called the TERT promoter—the third most common mutation among all human cancers and the most common mutation in the deadly brain cancer glioblastoma—confers ...

Unraveling the mystery of why cancer cells survive and thrive

January 30, 2017

Some cancer cells have a trick up their sleeve to avoid cell death: boosting maintenance of telomeres, the protective "end caps" on chromosomes, and a research team led by Jackson Laboratory (JAX) Professor Roel Verhaak reports ...

New mutations driving malignant melanoma discovered

January 24, 2013

Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't been previously ...

Targeting telomerase as therapeutic strategy for melanoma

April 25, 2018

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar ...

Recommended for you

Meteorite source in asteroid belt not a single debris field

February 17, 2019

A new study published online in Meteoritics and Planetary Science finds that our most common meteorites, those known as L chondrites, come from at least two different debris fields in the asteroid belt. The belt contains ...

Diagnosing 'art acne' in Georgia O'Keeffe's paintings

February 17, 2019

Even Georgia O'Keeffe noticed the pin-sized blisters bubbling on the surface of her paintings. For decades, conservationists and scholars assumed these tiny protrusions were grains of sand, kicked up from the New Mexico desert ...

Archaeologists discover Incan tomb in Peru

February 16, 2019

Peruvian archaeologists discovered an Incan tomb in the north of the country where an elite member of the pre-Columbian empire was buried, one of the investigators announced Friday.

Where is the universe hiding its missing mass?

February 15, 2019

Astronomers have spent decades looking for something that sounds like it would be hard to miss: about a third of the "normal" matter in the Universe. New results from NASA's Chandra X-ray Observatory may have helped them ...

What rising seas mean for local economies

February 15, 2019

Impacts from climate change are not always easy to see. But for many local businesses in coastal communities across the United States, the evidence is right outside their doors—or in their parking lots.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.